Using anti-inflammatory drugs and steroids to relieve pain could increase the chances of developing chronic pain, according to researchers from McGill University and colleagues in Italy. Their research puts into question conventional practices used to alleviate pain. Normal recovery from a painful injury involves inflammation and blocking that inflammation with drugs could lead to harder-to-treat pain.
It is increasingly clear that male and female humans and rodents process pain in different ways. And that there are important differences in the underlying mechanisms involved at genetic, molecular, cellular, and physiological levels. Despite this fact, according to a review paper from McGill University published today in Nature Reviews Neuroscience, most pain research remains overwhelmingly based on the study of male rodents, continuing to test hypotheses derived from earlier experiments on males.
Researchers at McGill University have discovered that a protein found in the membrane of our sensory neurons are involved in our capacity to feel mechanical pain, laying the foundation for the development of powerful new analgesic drugs.
The study, published in Cell, is the first to show that TACAN, a highly conserved protein among vertebrates whose function remained unclear, is in fact involved in detecting mechanical pain by converting mechanical pressures into electric signals.
Scientists increasingly believe that one of the driving forces in chronic pain—the number one health problem in both prevalence and burden—appears to be the memory of earlier pain. Research published today in Current Biology suggests that there may be variations, based on sex, in the way that pain is remembered in both mice and humans.
Pain researchers' arguments for using only male rodents in preclinical pain research don't hold up to scrutiny, says McGill neuroscientist Jeffrey Mogil. Nature
Antidepressant use in North America has increased over the last 2 decades. A suspected reason for this trend is that primary care physicians are increasingly prescribing antidepressants for nondepressive indications, including unapproved (off-label) indications that have not been evaluated by regulatory agencies.
The potential of light as a non-invasive, highly-focused alternative to pain medication was made more apparent thanks to research conducted by scientists at the Montreal Neurological Institute and Hospital of McGill University and the McGill University Health Centre.
By Cynthia Lee
In real estate, location is key. It now seems the same concept holds true when it comes to stopping pain. New research published in Nature Communications indicates that the location of receptors that transmit pain signals is important in how big or small a pain signal will be -- and therefore how effectively drugs can block those signals.
By Chris Chipello
A new study finds that rising placebo responses may play a part in the increasingly high failure rate for clinical trials of drugs designed to control chronic pain caused by nerve damage.
New research released today in Nature Neuroscience reveals for the first time that pain is processed in male and female mice using different cells. These findings have far-reaching implications for our basic understanding of pain, how we develop the next generation of medications for chronic pain—which is by far the most prevalent human health condition—and the way we execute basic biomedical research using mice.
An international study led by scientists at McGill University reports, for the first time, that drugs that selectively target the melatonin MT2 receptor represent a novel class of analgesic drugs that could be used to treat patients with neuropathic pain.
The ability to express empathy -- the capacity to share and feel another’s emotions -- is limited by the stress of being around strangers, according to a new study published today in the journal Current Biology.